Detail akcie Revance Therap online

Business Summary: Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to commercialize DAXXIFY in China. Its product/product candidate includes DAXXIFY for glabellar lines indication; DAXXIFY for cervical dystonia indication; RHA Redensity for perioral rhytids indication; RHA 2/ RHA 3/ RHA 4 for facial wrinkles and folds (such as nasolabial folds) indication; DAXXIFY for forehead lines, lateral canthal lines, upper facial lines indication; DAXXIFY for upper limb spasticity indication, and onabotulinumtoxinA biosimilar. The Company has exclusive right to import, market, promote, sell and distribute Teoxane's line of Resilient Hyaluronic Acid dermal fillers.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Revance Therapeutics Inc revenues increased 77% to $234M. Net loss decreased 9% to $324M. Revenues reflect Product revenue increase of 80% to $212.7M, Service revenue increase of 75% to $12.2M, Collaboration revenue increase of 23% to $9.1M. Lower net loss reflects Amortization decrease of 78% to $6.1M (expense), Research & Development balance decrease of 22% to $65.5M (expense).